Pharmasyntez announces the construction of a new Pharmasyntez-Medtech facility in Kaluga to produce medical equipment, supplies, and devices for dialysis.
Ensuring technological sovereignty and offering patients with chronic kidney disease all the treatment facilities they require in Russia are the global goal of the Pharmasyntez Group.м
In fact, the nation was reliant on imports for dialysis supplies, equipment, and infusion solutions back in 2023. The Pharmasyntez Group decided to make Russia nearly entirely independent of foreign equipment and supplies in this sector after the abrupt exit of the American company Baxter from the Russian market and the realization of the unpredictability of foreign supplies. “The project's first phase, which was started with a RUB 2 billion investment and a soft loan from the Federal Reserve Bank of Russia, is the beginning of a large-scale import substitution program for medical equipment and supplies for the treatment of renal failure” stated Vikram Punia, President of the Pharmasyntez Group of Companies.
The project's emphasis on the simultaneous development of two dialysis segments, hemodialysis and peritoneal dialysis, is one of its distinctive features. While the second is the only at-home dialysis technique available in Russia, the first is intended for blood purification in dialysis centers and critical care units.
All forms of dialysis products will be produced at the new Pharmasyntez-Medtech facility located in Kaluga's Rosva Industrial Park. The business is concentrating on its own advancements in equipment and supplies manufacturing. The initial phase of complex equipment production is carried out in collaboration with partners from friendly countries. Important hemodialysis supplies, such as dialyzers and blood tubing sets, as well as supplies for peritoneal dialysis, have been brought to market by Pharmasyntez R&D service after much effort. All components will be manufactured at Pharmasyntez-Medtech, and all polymers used in the production of dialyzer case parts and tubing components will be 100% Russian.
Nikolai Panikarovsky, Pharmasyntez-Medtech’s CEO:
"The majority of the supplies will be manufactured not just in Russia, but using Russian raw materials. In other words, the localization will be extremely deep. Establishing production of dialysis equipment with a 100% domestic design is Pharmasyntez's strategic goal. A gradual increase in the proportion of Russian components is part of this complex project. We work hard to ensure that new dialysis systems are available for domestic hospitals and to meet the high-quality standards set by Western manufacturers. In addition to developing and introducing the apparatus to the market, it is crucial to guarantee the availability of all supplies and to arrange for user medical and technical support”.
Our production capacity enables us to meet 75% to 100% of the demand for medical devices and supplies for hemodialysis as well as the full demand of Russian patients for supplies and medical devices for automated peritoneal dialysis and permanent outpatient dialysis.
Ninety percent of dialysis treatments in Russia are currently carried out with imported medical devices, many of which only use supplies from one company. Accelerating the shift to domestic open systems with universal supplies is therefore crucial, as it is an important step in guaranteeing patient drug safety.
Aleksei Katayev, Novadial’s CEO:
“If Pharmasyntez and we hadn't been able to find a way out of the current situation and provide a high-quality innovative solution for the Russian patient and the Russian healthcare system in the shortest amount of time, a large group of completely defenseless patients could have suffered very seriously. They will not survive long without dialysis, because they are chronic patients”.
Pharmasyntez is the only Russian company offering a complete range of dialysis solutions, including icodextrin-based glucose-free solution, and produces over 3 million liters of dialysis solutions annually. Pharmasyntez, the industry leader in government supply, made the decision to construct a new plant in Ussuriysk for the production of parenteral nutrition, which is scheduled to open this year. The Eastern Economic Forum (EEF) in September is when the opening is planned to take place. By the end of the year, the Pharmasyntez Group will have reached full production capacity and satisfied the nation's demand for these medications.